Advertisement

Disease Management and Health Outcomes

, Volume 5, Issue 2, pp 73–81 | Cite as

Guidelines for the Diagnosis and Treatment of Meningococcal Meningitis

Review Article
  • 7 Downloads

Abstract

Meningococcal disease may present as meningitis, septicaemia or a combination of the two. Generally, meningitis has a gradual onset, with fever, headache and neck stiffness as the most frequent clinical symptoms. In contrast, fulminant septicaemia may develop within hours, and is characterised by hypotension, disseminated intravasai coagulation (DIC), petecchial bleedings and shock. Mortality with septicaemia often reaches 30%.

It is of vital importance to diagnose and treat meningococcal disease rapidly. Conventionally, diagnosis is based on culture of the bacterium Neisseria meningitidis from blood or cerebrospinal fluid (CSF) or on microscopy of Gram-negative diplococci in the CSF. Direct bacterial antigen (capsular polysaccharide) detection methods have readily become available. These tests are rapid and do not require the presence of viable bacteria, but their sensitivity and specificity is low. During the last few years, a number of polymerase chain reaction (PCR) tests for the detection of bacterial nucleic acids have been developed. PCR tests are rapid, specific, extremely sensitive, does not require viable bacteria and may allow direct typing of the bacterium.

The drug of choice for treating meningococcal disease is benzylpenicillin. In some rare cases, the sensitivity of N. meningitidis to penicillin is decreased, and ceftriaxone or cefotaxime may be used instead. The severe clinical signs in septicaemia are mainly caused by bacterial endotoxins which are part of the bacterial cell wall and are also released from viable bacteria. Antibiotics do not prevent the effects of endotoxins and supportive therapy to control increased intracranial pressure, hypovolaemia, DIC and shock, are also needed. Following the first case of meningococcal disease in a population, the infection may spread causing one or more secondary cases. The ideal prevention of meningococcal disease is by vaccination. However, no vaccine against group B meningococcal disease exists, and group A and C vaccines have not been implemented in most vaccination programmes. Prevention of the primary case is therefore not achievable, but secondary infection can be prevented by eradication of the disease-causing strain in healthy contacts with chemoprophylaxis.

Keywords

Meningitis Adis International Limited Bacterial Meningitis Capsular Polysaccharide Meningococcal Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Boslego JW, Tramont EC. Neisseria meningitidis. In: Gorbach SL, Bartlett JG, Blacklow NR, editors. Infectious diseases. 2nd ed. Philadelphia: WB Saunders Company, 1998: 769–75Google Scholar
  2. 2.
    American Academy of Pediatrics, Meningococcal Infections. In: Peter G, editor. Red book: Report of the Committee on Infectious Diseases. 24th ed. Elk Grove Village (IL): American Academy of Pediatrics, 1997: 357–62Google Scholar
  3. 3.
    Halstensen A, Pedersen SHJ, Haneberg B, et al. Case fatality of meningococcal disease in Western Norway. Scand J Infect Dis 1987; 19: 35–42PubMedCrossRefGoogle Scholar
  4. 4.
    Schwartz M. Acute bacterial meningitis. In: Gorbach SL, Bartlett JG, Blacklow NR, editors. Infectious diseases. 2nd ed. Philadelphia: WB Saunders Company, 1998: 1382–408Google Scholar
  5. 5.
    Caugant DA, Frøholm LO, Borre K, et al. Intercontinental spread of a genetically distinct complex of clones of Neisseria meningitidis causing epidemic disease. Proc Natl Acad Sci USA 1986; 83: 4927–31PubMedCrossRefGoogle Scholar
  6. 6.
    Bjorvatn B, Lund V, Kristiansen BE, et al. Applications of restriction endonuclease fingerprinting of chromosomal DNA of Neisseria meningitidis. J Clin Microbiol 1984; 19: 763–5PubMedGoogle Scholar
  7. 7.
    Kristiansen BE, Tveten Y, Ask ER, et al. Preventing secondary cases of meningococal disease by identifying and eradicating disease-causing strains in close contacts of patients. Scand J Infect Dis 1992; 24: 165–73PubMedCrossRefGoogle Scholar
  8. 8.
    Kristiansen BE, Fermer C, Jenkins A, et al. PCR amplicon restriction endonuclease analysis of the chromosomal dhps gene of Neisseria meningitidis: a method for studying the spread of the disease-causing strain in contacts with patients with meningococcal disease. J Clin Microbiol 1995; 33: 1174–9PubMedGoogle Scholar
  9. 9.
    Woods CR, Koeuth T, Eastbrook MM, et al. Rapid determination of outbreak-related strains of Neisseria meningitidis by repetitive element-based polymerase chain reaction genotyping. J Infect Dis 1996; 174: 760–7PubMedCrossRefGoogle Scholar
  10. 10.
    Infectious diseases kill over 17 million people a year: WHO warns of global crisis [online]. Available from: URL: http://www.who.ch/programmes/whr/1996/pressl.htm [Accessed 1996 Aug 30]
  11. 11.
    Steering Committee on Meningococcal and Pneumococcal Disease Vaccines. Vaccine and Immunization News. No.1. Geneva: WHO, 1996: JuneGoogle Scholar
  12. 12.
    Moore PS, Reeves MW, Schwartz B, et al. Intercontinental spread of an epidemic group A Neisseria meningitidis strain. Lancet 1989; II: 260–3CrossRefGoogle Scholar
  13. 13.
    Schucat A, Robinson K, Wenger JD. Bacterial meningitis in the United States in 1995. N Engl J Med 1997; 337: 970–6CrossRefGoogle Scholar
  14. 14.
    Flægstad T, Kaaresen PI, Stokland T, et al. Factors associated with fatal outcome in meningococcal disease. Acta Paediatr 1995; 84: 1137–42PubMedCrossRefGoogle Scholar
  15. 15.
    Benenson AS, editor. Control of communicable disease. 16th ed. Washington, DC: American Public Health Association. 1995: 303–7Google Scholar
  16. 16.
    Control of meningococcal disease: guidance for consultants in communicable disease control. CDR Review 1995; 5: R196-8Google Scholar
  17. 17.
    Høiby EA, Bruun J, Andrew M, et al. Guidelines for diagnosis and treatment of systemic meningococcal disease [in Norwegian]. Oslo: National Institute of Public Health, IK-2297, 1989Google Scholar
  18. 18.
    Gold R. Clinical aspects of meningococcal disease. In: Vedros NA, editor. Evolution of meningococcal disease. Vol IL Boca Raton (FL): CRC Press, 1987: 69–97Google Scholar
  19. 19.
    Wylie PAL, Stevens D, Drake III W, et al. Epidemiology and clinical management of meningococcal disease in west Gloucestershire: retrospective, population based study. BMJ 1997; 315: 774–9PubMedCrossRefGoogle Scholar
  20. 20.
    Nato F, Mazie C, Fournier JM, et al. Production of polyclonal and monoclonal antibodies agaisnt A, B and C capsular poly-saccharides of Neisseria meningitidis and preparation of latex reagents. J Clin Microbiol 1991; 29: 1447–52PubMedGoogle Scholar
  21. 21.
    Barnes RA, Jenkins P, Coakley WT. Preliminary clinical evaluation of meningococcal disease and bacterial meningitis by ultrasonic enhancement. Arch Dis Child 1998; 78: 58–60PubMedCrossRefGoogle Scholar
  22. 22.
    Kristiansen BE, Ask E, Jenkins A, et al. Rapid diagnosis of meningococcal meningitis by polymerase chain reaction. Lancet 1991; 337: 1568–9PubMedCrossRefGoogle Scholar
  23. 23.
    Ni H, Knight AI, Palmer WH, et al. PCR in the diagnosis of meningococcal meningitis. Lancet 1992; 340: 1432–4PubMedCrossRefGoogle Scholar
  24. 24.
    Newcombe J, Cartwright K, Palmer WH, et al. PCR of peripheral blood for the diagnosis of meningococcal disease. J Clin Microbiol 1996; 34: 1637–40PubMedGoogle Scholar
  25. 25.
    Borrow R, Claus H, Chaudhry U, et al. siaD PCR ELISA for confirmation and identification of serogroup Y and W135 meningococcal infections. FEMS Microbiol Lett 1998; 159: 209–14PubMedCrossRefGoogle Scholar
  26. 26.
    Olcén P, Lantz PG, Backman A, et al. Rapid diagnosis of bacterial meningitis by seminested PCR strategy. Scand J Infect Dis 1995; 27: 537–9PubMedCrossRefGoogle Scholar
  27. 27.
    Borrow R, Claus H, Guiver M, et al. Non-culture diagnosis and serogroup determination of meningococcal B and C infection by a sialyltransferase (sial) PCR ELISA. Epidemiol Infect 1997; 118: 111–7PubMedCrossRefGoogle Scholar
  28. 28.
    Wald ER, Kaplan SI, Mason Jr EO, et al. Dexamethasone therapy for children with bacterial meningitis. Pediatrics 1995; 95: 21–8PubMedGoogle Scholar
  29. 29.
    Girgis NI, Farid Z, Mikhail IA, et al. Dexamethasone treatment for bacterial meningitis in children and adults. Pediatr Infect Dis J 1989; 8: 848–51PubMedCrossRefGoogle Scholar
  30. 30.
    Zahlen A, Nydegger UE, Vaudaux P, et al. Complement-mediated opsonic activity in normal and infected human cerebrospinal fluid: early response during bacterial meningitis. J Infect Dis 1982; 145: 635–46CrossRefGoogle Scholar
  31. 31.
    Tauber MG, Doroshow CA, Hackbarth CJ, et al. Antibacterial activity of beta-lactam antibiotics in experimental meningitis due to Streptococcus pn. eumoniae. J Infect Dis 1984; 149: 568–74PubMedCrossRefGoogle Scholar
  32. 32.
    Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med 1997; 336: 708–14PubMedCrossRefGoogle Scholar
  33. 33.
    Tunkel AR, Scheld WM. Acute bacterial meningitis. Lancet 1995; 346: 1675–80PubMedCrossRefGoogle Scholar
  34. 34.
    Cartwright K, Strong J, Gossain S, et al. Early treatment of meningococcal disease. BMJ 1992; 305: 774PubMedCrossRefGoogle Scholar
  35. 35.
    Dillon JR, Pauze M, Yeung K-H. Spread of penicillinase-producing and transfer plasmids from the gonococcus to Neisseria meningitidis. Lancet 1983; I: 779–81CrossRefGoogle Scholar
  36. 36.
    Van Esso D, Fontanals D, Uriz S, et al. Neisseria meningitidis strains with decreased susceptibility to penicillin. Pediatr Infect Dis J 1987; 6: 438–9PubMedCrossRefGoogle Scholar
  37. 37.
    Suez-Nieto JA, Lujan R, Berron S, et al. Epidemiology and molecular basis of penicillin-resistant Neisseria meningitidis in Spain: a 5-year history (1985-1989). Clin Infect Dis 1994; 170: 453–6Google Scholar
  38. 38.
    Sutcliff EM, Jones DM, el-Sheikh S, et al. Penicillin-insensitive meningococci in the UK. Lancet 1988; I: 657CrossRefGoogle Scholar
  39. 39.
    Jones DM, Sutcliff EM. Meningococci with reduced susceptibility to penicillin. Lancet 1990; 335: 863–4PubMedCrossRefGoogle Scholar
  40. 40.
    Jackson LA, Tenover FC, Baker C, et al. Prevalence of Neisseria meningitidis relatively resistant to penicillin in the United States 1991. J Infect Dis 1994; 169: 438–41PubMedCrossRefGoogle Scholar
  41. 41.
    Peltola H, Käyhty H, Kuronen T, et al. Meningococcus group A vaccine in children three months to five years of age. Adverse reactions and immunogenicity related to endotoxin content and molecular weight of the polysaccharide. J Pediatr 1978; 92: 818–22PubMedCrossRefGoogle Scholar
  42. 42.
    Gold R, Lepow ML, Goldschneider I, et al. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administrated during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis 1979; 140: 690–7PubMedCrossRefGoogle Scholar
  43. 43.
    Bjune G, Høiby EA, Grønnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991; 338: 10936CrossRefGoogle Scholar
  44. 44.
    de Moraes JC, Perkins BA, Camargo MCC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992; 340: 1074–8PubMedCrossRefGoogle Scholar
  45. 45.
    Perkins BA, Jonsdottir K, Briem H. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis 1998; 177: 683–91PubMedCrossRefGoogle Scholar
  46. 46.
    Haneberg B, Dalseg R, Wedege E, et al. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect Immun 1998; 66: 1334–41PubMedGoogle Scholar
  47. 47.
    Kristiansen BE, Jenkins A. Preventing the spread of meningococcal infection. Dis Manage Health Outcome 1997; 1: 233–40CrossRefGoogle Scholar
  48. 48.
    Olcén P, Kjellander J, Danielsson, et al. Epidemiology of Neisseria meningitidis: prevalence and symptoms from the upper respiratory tract in family members to patients with meningococcal disease. Scand J Infect Dis 1981; 13: 105–9PubMedGoogle Scholar
  49. 49.
    Kristiansen BE, Jenkins A, Tveten Y. Meningococcal disease — who carries the disease-causing strain? BMJ 1998; 317: 621–5PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  1. 1.Telemark Biomedical Centre and University of TromsøTromsøNorway
  2. 2.University Hospital of TromsoTromsoNorway

Personalised recommendations